The Marked Chart Wire · Series of events
Series of events · Novartis
Novartis lifts profit outlook after drug trial success
Novartis raised its 2026 earnings forecast following a successful trial for a rare cancer drug and despite charges for failed projects.
Updated
The flow in 3 points
- Remibrutinib cut relapse rates by 35 percent in trials
- Core earnings growth forecast raised to low single digits
- Failed drug charges totaled $2.2 billion
What happened, in order
Times are Eastern-
Where it began
Trial goals met
Novartis reported that remibrutinib met primary endpoints in phase 3 trials for rhabdomyosarcoma, cutting relapse rates by 35 percent.
Read the story -
Forecast lifted
The company raised its expected growth in core earnings to in line to low single digits while keeping its net sales projection unchanged.
Read the story -
Latest
Charges booked
Novartis booked $2.2 billion in charges for failed drugs, causing reported operating income to drop 61 percent, but core income rose 10 percent.
Read the story
How they connect
Novartis first announced that its cancer drug met trial goals. The company then raised its profit forecast while noting that charges for failed drugs reduced reported operating income.
The stocks in this series
Prices from Live · updated 10:54 AM ET. Each tile opens the stock's chart and news.
A series is a short summary of connected news, for learning. Not verified and not advice. Check the full stories before you act.